São Paulo - Delayed Quote BRL

Moderna, Inc. (M1RN34.SA)

7.00
+0.14
+(2.04%)
At close: May 16 at 8:33:27 PM GMT-3
Loading Chart for M1RN34.SA
  • Previous Close 6.86
  • Open 0.00
  • Bid 6.86 x --
  • Ask 7.45 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 44.00
  • Volume 0
  • Avg. Volume 54,553
  • Market Cap (intraday) 54.651B
  • Beta (5Y Monthly) 2.00
  • PE Ratio (TTM) --
  • EPS (TTM) -2.48
  • Earnings Date Jul 30, 2025 - Aug 4, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

www.modernatx.com

5,800

Full Time Employees

December 31

Fiscal Year Ends

Recent News: M1RN34.SA

View More

Performance Overview: M1RN34.SA

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

M1RN34.SA
42.72%
S&P 500 (^GSPC)
1.30%

1-Year Return

M1RN34.SA
79.44%
S&P 500 (^GSPC)
12.48%

3-Year Return

M1RN34.SA
79.65%
S&P 500 (^GSPC)
48.66%

5-Year Return

M1RN34.SA
67.85%
S&P 500 (^GSPC)
108.07%

Compare To: M1RN34.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: M1RN34.SA

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    54.65B

  • Enterprise Value

    24.92B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.02

  • Price/Book (mrq)

    0.95

  • Enterprise Value/Revenue

    1.40

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -105.67%

  • Return on Assets (ttm)

    -15.84%

  • Return on Equity (ttm)

    -29.34%

  • Revenue (ttm)

    3.18B

  • Net Income Avi to Common (ttm)

    -3.36B

  • Diluted EPS (ttm)

    -2.48

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.98B

  • Total Debt/Equity (mrq)

    7.40%

  • Levered Free Cash Flow (ttm)

    -3.2B

Research Analysis: M1RN34.SA

View More

Company Insights: M1RN34.SA

Research Reports: M1RN34.SA

View More

People Also Watch